As the year winds down, investors may be looking forward to 2023 and hoping for a better year in the stock market. Part of this growth is due to sales of consumables, which increased 53% year over year, outpacing revenue growth.
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is proud to announce the Health Canada license of the Forma-I to address the symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). Forma-I is intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation.
A stock that scores a perfect 10 should be on every investor’s list of stocks to buy. Any company that receives full marks on quality, value, or growth are stocks I’d considering a perfect 10. For this article, I’m using StockRover’s stock screening tool, which screens for such qualities among a very large basket of companies. Despite many of these stocks to buy scoring so highly on one particular attribute, the market has heavily discounted most of these companies. Thus, it appears a tug-of-war